CD14 : a candidate biomarker for the prognosis of polycystic kidney disease

Gregory B Vanden Heuvel1

  • 1Department of Anatomy and Cell Biology and the Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas 66160, USA. gvandenheuvel@kumc.edu

Kidney International
|September 1, 2010
PubMed

Insights

CD14 expression indicates disease progression in polycystic kidney disease (PKD). This immune marker is found in renal tubule cells, suggesting early Toll-like receptor-4 activation in PKD.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Polycystic kidney disease (PKD) is a genetic disorder characterized by cyst formation in the kidneys.
  • The role of the innate immune system in PKD pathogenesis is not fully understood.

Purpose of the Study:

  • To investigate the expression of innate immune markers in different models of PKD.
  • To determine the correlation between CD14 expression and PKD progression.
  • To explore the cellular origin of CD14 in the kidney and its implications for PKD.

Main Methods:

  • Analysis of CD14 expression in the cpk mouse model of PKD.
  • Examination of CD14 expression in human recessive and autosomal dominant PKD samples.
  • Correlation analysis between CD14 levels and disease severity.
  • Immunohistochemical analysis to identify CD14-expressing cells in the kidney.

Main Results:

  • CD14 expression is validated in the innate immune system of PKD models and human patients.
  • CD14 expression levels correlate with the progression of PKD, including early stages.
  • CD14 is expressed by renal tubule epithelial cells, not solely inflammatory cells.

Conclusions:

  • CD14 is a potential biomarker for PKD progression.
  • Renal tubule epithelial cell expression of CD14 suggests an intrinsic mechanism of Toll-like receptor-4 activation in PKD.
  • This activation may precede inflammatory cell infiltration in PKD pathogenesis.